Quantcast

Latest Orphan drug Stories

2014-02-25 08:32:12

EASTBOURNE, England, February 25, 2014 /PRNewswire/ -- Daval International, the emerging life sciences company focused on the development of novel treatments for serious unmet medical needs, today announced receipt of Orphan Drug Designation from the U.S. Food and Drug Administration (FDA), Office of Orphan Products Development, for AIMSPRO(R) for the treatment of systemic sclerosis (scleroderma). "The granting of Daval's request for Orphan Drug Designation represents a...

2014-02-25 08:30:35

LOS ANGELES, Feb. 25, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced that the European Medicines Agency (EMA) has granted orphan drug designation for ICT-107 for the treatment of patients with glioblastoma. Granting of orphan drug status in the EU provides sponsor companies with incentives, including a 10-year period of market exclusivity, access to a centralized review process, trial design assistance and scientific advice during...

2014-02-24 04:21:52

ALISO VIEJO, Calif., Feb. 24, 2014 /PRNewswire/ -- Global Genes (globalgenes.org), a leading patient advocacy organization representing the rare and genetic disease community, is once again inviting industry partners, patients, caregivers, family and friends of the tens of millions of people who suffer from rare and genetic diseases to Wear That You Care(TM) and support the seventh annual World Rare Disease Day on Friday, February 28, 2014. The Wear That You Care(TM) campaign was launched by...

2014-02-19 04:22:21

Full Service CRO WCCT Global announces program for orphan drug development. COSTA MESA, Calif., Feb. 19, 2014 /PRNewswire-iReach/ -- WCCT Global, a multi-site full service CRO that is headquartered in Southern California announced today a specialized program to conduct clinical research for sponsors who are engaged in orphan drug development. Aside from the often referenced technical and commercial hurtles which must be overcome before deciding to launch the development program for...

2014-02-14 23:21:13

MarketReportsOnline.com adds "US Orphan Drug Market Outlook 2018" report to its research store. Dallas, Texas (PRWEB) February 14, 2014 In the largest market for orphan drugs, USA, there was a shortage of adequate therapies for treating many rare diseases. These therapies were not developed as companies did not expect these drugs to be highly profitable. Hence there was a lack of interest and thus investment on the part of pharma companies in the USA. Therefore, the FDA...

2014-02-13 12:21:35

DUBLIN, Feb. 13, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/kknn78/orphan_drugs_in ) has announced the addition of Just Pharma Reports's new report "Orphan Drugs in Europe: Pricing, Reimbursement, Funding & Market Access Issues" to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) The cost of treating rare disease in an age when austerity measures are hitting total healthcare funding across Europe is a...

2014-02-07 08:22:40

NEW DELHI, February 7, 2014 /PRNewswire/ -- KuicK Research releases "Global Orphan Drug Market Outlook 2018" research report offering comprehensive insight on recent trends, regulatory development related to US orphan drug market, Europe orphan drug market & Asia orphan drug market. Report also gives insight on more than 600 orphan drugs in clinical pipeline and 231 marketed orphan drugs. Global Orphan Drug Market Report Findings: - Orphan...

2014-02-04 23:00:35

EPI-743 phase 2b Friedreich's ataxia trial fully enrolled. Downingtown, PA (PRWEB) February 04, 2014 Edison Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to vatiquinone (EPI-743) for the treatment of Friedreich’s ataxia (http://www.prnewswire.com/news-releases/fda-grants-edison-pharmaceuticals-epi-743-orphan-status-for-friedreichs-ataxia-243439351.html). Orphan status brings additional momentum and acceleration to the...

2014-02-04 00:21:05

EPI-743 in phase 2 development for Friedreich's ataxia MOUNTAIN VIEW, Calif., Feb. 4, 2014 /PRNewswire/ -- Edison Pharmaceuticals today announced that the US Food and Drug Administration has granted Orphan Status to vatiquinone for the treatment of Friedreich's ataxia. Vatiquinone is the International Nonproprietary Name (INN) for Edison's EPI-743. The INN is a unique international name issued by the World Health Organization. It is used to identify the active pharmacological...

2014-01-29 23:25:48

Keller brings strong niche brand experience to high science agency. Chicago, IL (PRWEB) January 29, 2014 Discovery USA, a high-science marketing and communications agency and part of Publicis Healthcare Communications Group (PHCG), announced the appointment of Kristin M. Keller as Executive Vice President, Client Engagement. In this role, Keller is responsible for expanding Discovery’s offerings, ensuring Discovery’s clients are connected to the full range of services and expertise...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related